Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2021

Apr 26, 2021

SELL
$9.26 - $14.36 $926 - $1,436
-100 Closed
0 $0
Q4 2020

Jan 21, 2021

SELL
$9.84 - $14.26 $9,840 - $14,260
-1,000 Reduced 90.91%
100 $0
Q3 2020

Oct 27, 2020

BUY
$10.3 - $21.64 $9,270 - $19,476
900 Added 450.0%
1,100 $0
Q2 2020

Jul 22, 2020

BUY
$8.53 - $25.64 $852 - $2,564
100 Added 100.0%
200 $0
Q1 2020

May 07, 2020

SELL
$7.98 - $16.32 $32,718 - $66,912
-4,100 Reduced 97.62%
100 $0
Q4 2019

Feb 06, 2020

SELL
$5.12 - $12.22 $200,704 - $479,024
-39,200 Reduced 90.32%
4,200 $7,000
Q3 2019

Oct 28, 2019

BUY
$5.24 - $15.89 $227,416 - $689,626
43,400 New
43,400 $4,000

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $424M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.